Yubal, Dasch H.

HRN: 18-91-99  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/20/2023
CEFUROXIME 750MG (VIAL)
10/20/2023
10/27/2023
IV
500mg
Q8h
Uti
Checking Final Appropriateness 
10/21/2023
NYSTATIN 100,000IU/ML, 30ML SUSPENSION (BOT)
10/21/2023
10/28/2023
TOPICAL
1ml
QID
Mouth Sores
Checking Final Appropriateness 
10/22/2023
CEFTRIAXONE 1G (VIAL)
10/22/2023
10/29/2023
IV
1.6gms
OD
Dengue Fever W/ WS; UTI
Checking Final Appropriateness 
10/22/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
10/22/2023
10/29/2023
IV
160mg
TID
Dengue Fever W/ WS; UTI
Checking Final Appropriateness 
10/22/2023
FLUCONAZOLE 2MG/ML, 100ML (VIAL)
10/22/2023
10/29/2023
IV
95mg
OD
Dengue Fever W/ WS; UTI
Checking Final Appropriateness 
10/22/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
10/22/2023
10/29/2023
IV
80mg
TID
Dengue Fever With WS
Checking Final Appropriateness 
10/26/2023
MUPIROCIN 2%, 15G (TUBE)
10/26/2023
11/01/2023
TOPICAL
1squirt
BID
Phlebitis
Checking Final Appropriateness 
10/26/2023
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
10/26/2023
11/01/2023
IVT
1,200mg
Q8
Sepsis
Checking Final Appropriateness 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: